
Product Data Sheet

Product Name: STX-0119

Cat. No.: GC67779

Chemical Properties

Cas. No. 851095-32-4

Formula $C_{22}H_{14}N_4O_3$ M.Wt 382.37

Solubility Storage 4°C, protect from light

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

Background

STX-0119 is a selective, orally active **STAT3** dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an **IC₅₀** of 74 μM ^[1].

STX-0119 (10-50 μM ; 24 h) inhibits STAT3 dimerization through a direct interaction with the STAT3 protein and not via the modulation of upstream regulators such as JAK in HEK293 and MDA-MB-468 cells^[1].

STX-0119 (10-50 μM ; 24 h) reduces the expression of STAT3 target proteins^[1].

Western Blot Analysis^[1]

Cell Line: MDA-MB-468 cells

Concentration: 10, 20 and 50 μM

Incubation Time: 24 h

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Result: Reduced the expression of STAT3 target proteins, namely, c-myc, cyclin D1, and survivin, in a concentration-dependent manner. Did not suppress the expression of those STAT3-regulated oncoproteins.

STX-0119 (160 mg/kg; oral gavage; daily for 4 days) inhibits SCC-3 tumor growth in mice^[1].

The plasma concentration of STX-0119 (160 mg/kg; oral gavage) is maintained at >100 µg/mL (>260 µM), even at 8 h after administration^[1].

Animal Model: Male BALB/cA-N/N nude mice, SCC-3 lymphoma xenograft model^[1]

Dosage: 160 mg/kg

Administration: Oral gavage, daily for 4 days

Result: Suppressed the growth of SCC-3 cells significantly on the fourth day.

[1]. Matsuno K, et al. Identification of a New Series of STAT3 Inhibitors by Virtual Screening. ACS Med Chem Lett. 2010 Jul 13;1(8):371-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA